Evidence map›Paper›PMID 38388550›Full record

ArticleScientific reports2024

Repeated microdoses of LSD do not alter anxiety or boldness in zebrafish.

Ethan V Hagen, Melike Schalomon, Yanbo Zhang, Trevor J Hamilton

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ethan V HagenDepartment of Psychiatry, University of Alberta, Edmonton, AB, Canada.
Melike SchalomonDepartment of Psychology, MacEwan University, 10700 104 Ave NW, Edmonton, AB, T5J 4S2, Canada.
Yanbo ZhangDepartment of Psychiatry, University of Alberta, Edmonton, AB, Canada.
Trevor J HamiltonDepartment of Psychology, MacEwan University, 10700 104 Ave NW, Edmonton, AB, T5J 4S2, Canada. trevorjameshamilton@gmail.com.
MacEwan University · CAUniversity of Alberta · CA

Funding

Natural Sciences and Engineering Research Council of Canada TJH - 05426Start-up fund, University of Alberta, Canada RES0052505
6 · The paper itself

Abstract

The therapeutic use of lysergic acid diethylamide (LSD) has resurfaced in the last decade, prompting further scientific investigation into its effectiveness in many animal models. Zebrafish (Danio rerio) are a popular model organism in medical sciences and are used to examine the repeated administration of pharmacological compounds. Previous zebrafish research found acute LSD altered behaviour and cortisol levels at high (250 µg/L) but not low (5-100 µg/L) levels. In this study, we used a motion tracking system to record and analyze the movement patterns of zebrafish after acute and repeated 10-day LSD exposure (1.5 µg/L, 15 µg/L, 150 µg/L) and after seven days of withdrawal. The open-field and novel object approach tests were used to examine anxiety-like behaviour, boldness, and locomotion. In the acute experiments we observed a significant decrease in high mobility with 1.5 µg/L, 15 µg/L, and 150 µg/L of LSD compared to the control and a decrease in velocity with 1.5 and 15 µg/L. In repeated experiments, there were no significant differences in the levels of anxiety, boldness, or locomotion between all LSD groups and controls immediately after 10-day treatment or after withdrawal.

Indexed as

HallucinogensLysergic Acid DiethylamideAnimalsAnxietyLocomotionModels, AnimalZebrafishHallucinogensLysergic Acid Diethylamide

Identifiers

PMID38388550
PMCPMC10883969
OpenAlexW4392048822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.